Pharmafile Logo
Pharmafocus logo
Advanced Search

lung cancer

Showing 15 posts of 186 posts found.

shutterstock_gonnorrhea

Transgene ceases development of failed advanced non-squamous non-small cell lung cancer immunotherapy candidate

December 16, 2019
Research and Development, Sales and Marketing Cancer, Transgene, lung cancer, pharma

Cancer immunotherapeutics firm Transgene has confirmed that it is to terminate further development of its TG4010 candidate in the first-line …

News
top_10_image_43_0

Top Ten most popular articles on Pharmafile.com this week

December 6, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, FDA, NHS, corruption, lung cancer, opiods crisis, opioids

Corruption and bribery feature heavily in the news this week. A recently exposed 1997 email chain shows Dr Richard Sackler, …

News
contraceptive-pills-849413_960_720

Male birth control drug may hold promise for treating lung cancer, Chinese study finds

December 4, 2019
Research and Development Cancer Immunotherapy, Chinese Pharmaceuticals, Male Birth Control, lung cancer

A drug for male birth control may hold promise for treating lung cancer patients when treatments like immunotherapy do not …

News

FDA gives priority review for AstraZeneca’s Imfinzi

November 29, 2019
Medical Communications AstraZeneca, Cancer, FDA, Imfinzi, lung cancer

The FDA has granted a priority review of AstraZeneca’s cancer treatment drug Imfinzi (durvalumab) for treatment of patients with untreated …

News

AstraZeneca’s Imfinzi triple combo beats chemo in treatment-naive metastatic lung cancer

October 29, 2019
Manufacturing and Production, Research and Development AstraZeneca, Cancer, Imfinzi, NSCLC, lung cancer, pharma

AstraZeneca has unveiled positive new Phase 3 data for the combination of Imfinzi (durvalumab) and anti-CTLA4 antibody tremelimumab with chemotherapy …

News
opdivo_1_1

BMS’ Opdivo+Yervoy+Chemo combo shows superior overall survival in first-line lung cancer

October 23, 2019
Research and Development Bristol-Myers Squibb, Cancer, NSCLC, Yervoy, lung cancer, opdivo, pharma

Bristol Myers Squibb has lifted the curtain on new Phase 3 data for its blockbuster immunotherapy Opdivo (nivolumab), showing that …

News
lung_ambition_alliance

The Lung Ambition Alliance: Stronger together

October 9, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, lung cancer, pharma

Following our piece by AstraZeneca’s Patrick Connor introducing the Lung Ambition Alliance, a new cross-functional collaboration which aims to double …

Feature

Breaking through limits in lung cancer: Introducing the Lung Ambition Alliance

October 7, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Lung Ambition Alliance, feature, lung cancer, pharma

Lung cancer kills more patients than any other variety of cancer, accounting for around a fifth of all cancer-related deaths …

Feature
merckwindow_web

Scotland approves first-line NHS use of MSD’s Keytruda combo for advanced non-small cell lung cancer

October 7, 2019
Sales and Marketing Cancer, NHS, Scotland, Scottish Medicines Consortium, UK, keytruda, lung cancer, pharma

The Scottish Medicines Consortium (SMC) has announced its decision to accept MSD’s blockbuster immunotherapy Keytruda (pembrolizumab) in combination with pemetrexed …

News
astrazeneca_building_white

AZ’s Tagrisso extends median overall survival by over 3 years in metastatic, EGFR-mutated lung cancer

September 30, 2019
Research and Development, Sales and Marketing AstraZeneca, Cancer, ESMO 2019, Tagrisso, lung cancer, pharma

AstraZeneca took to the stage at the 2019 European Society for Medical Oncology (ESMO) Congress in Barcelona to present new …

News
lung_ambition_alliance

Breaking through limits in lung cancer: Introducing The Lung Ambition Alliance

September 16, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Cancer, Lung Ambition Alliance, lung cancer, oncology, pharma

Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, at AstraZeneca, discusses his company’s role in the …

Feature
pharmafocus_sept_2019_cover

Read the September edition of Pharmafocus online now!

September 12, 2019
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, brexit, lung cancer, medicinal cannabis, pharma

The latest monthly edition of Pharmafocus, the September issue, is available to read for free online now!With a new Prime …

News
opdivo_1_1

BMS unveils strong five-year efficacy data for Opdivo in lung cancer

September 11, 2019
Research and Development Bristol-Myers Squibb, Cancer, immunotherapy, lung cancer, pharma

Bristol-Myers Squibb has unveiled pooled five-year efficacy and safety results for its blockbuster immunotherapy Opdivo (nivolumab) drawn from two Phase …

News
merck-keytruda

MSD’s Keytruda approved for first-line lung cancer use on NHS Scotland

September 10, 2019
Manufacturing and Production, Sales and Marketing Cancer, MSD, SMC, Scotland, keytruda, lung cancer, pharma

MSD and lung cancer patients will be celebrating the news that the pharma giant’s immunotherapy Keytruda (pembrolizumab) has been accepted …

News
lilly_entrance_web

Lilly’s LOXO-292 shrinks tumours in lung cancer trial

September 9, 2019
Research and Development, Sales and Marketing Cancer, Eli Lilly, lung cancer, pharma

Eli Lilly has announced its experimental cancer drug LOXO-292, acquired in January, shrank tumours in almost 70% of advanced lung …

News

Latest content

Regeneron shares data for multiple myeloma treatment

December 8, 2023

Merck collaborates with Acceleration Consortium for AI experimentation

December 8, 2023

AbbVie to acquire Cerevel Therapeutics for approximately $8.7bn

December 7, 2023

ONK Therapeutics and NAYA Biosciences enter partnership for NK cell therapy development

December 7, 2023

FDA approves Novartis’ Fabhalta for PNH treatment

December 6, 2023